Aarey Drugs & Pharmaceuticals Limited (NSE: AAREYDRUGS | BSE: 524412)
Source: Aarey Drugs & Pharmaceuticals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Aarey Drugs & Pharmaceuticals Limited operates as an integrated chemical manufacturer and bulk drug trading entity within India’s pharmaceutical ecosystem. The company operates across two complementary business channels: custom synthesis and manufacturing of active pharmaceutical ingredients (APIs) and advanced chemical intermediates, combined with large-scale industrial trading of industrial solvents, chemicals, and pharmaceutical raw materials.
- Active Pharmaceutical Ingredients (APIs): Commercial manufacturing of Metformin HCL (anti-diabetic), Mefenamic Acid (non-steroidal anti-inflammatory), and Doxofylline (bronchodilator/respiratory).
- Advanced Chemical Intermediates: Synthesis of Mono Methyl Urea (MMU), Dimethyl Urea (DMU), Ortho Para Nitro Anisole (OPNA), Uracil, and 2-Bromomethyl 1,3-Dioxolane.
- Backward & Forward Integration Pipeline: Active development of domestic manufacturing capacities for Dimethylamine Hydrochloride (DMA-HCL), Ortho-Chlorobenzoic Acid, and Theophylline.
- Industrial Solvent Trading: Wholesale distribution of bulk chemical solvents, pharmaceutical raw materials, and organic reagents to domestic formulators.
📋 Quick Facts / Company Snapshot: Aarey Drugs & Pharmaceuticals Limited (NSE: AAREYDRUGS | BSE: 524412)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Aarey Drugs & Pharmaceuticals Limited |
| Corporate Identity Number (CIN) | L99999MH1990PLC056538 |
| ISIN | INE198H01019 |
| Stock Exchange Listing | BSE Scrip Code: 524412 | NSE Symbol: AAREYDRUGS |
| Date of Incorporation / Founding Year | 1990 |
| Registered Office | E-34, M.I.D.C., Tarapur, Boisar, Dist. Thane / Palghar, Pincode – 401506, Maharashtra |
| Head Office | 107, Sahakar Bhavan, 340/348, Narshi Natha Street, Masjid, Mumbai – 400009, Maharashtra |
| Telephone & Email | Tel: (022) 23455543 / (02525) 271049 | Email: corporate@aareydrugs.com / info@aareydrugs.com |
| Chairman & Managing Director | Mihir Rajesh Ghatalia |
| Executive Director | Nimit Rajesh Ghatalia |
| Chief Financial Officer (CFO) | Mira Mihir Ghatalia |
| Company Secretary & Compliance Officer | Kailash Chand Jethlia |
| Promoter Group | Ghatalia Family (Holding 37.71% equity stake) |
| Industry / Sector Classification | Pharmaceuticals & Chemicals / Active Pharmaceutical Ingredients (APIs) & Bulk Drug Intermediates |
| Manufacturing Plants | E-34, M.I.D.C. Tarapur, Boisar, District Palghar, Maharashtra |
| Credit Rating | ACUITE BBB / Outlook: Stable (Assigned by Acuité Ratings & Research) |
| Statutory Auditors | M/s. Motilal & Associates LLP, Chartered Accountants |
| Secretarial Auditor | M/s. Ashika Shetty, Practicing Company Secretary |
| Registrar and Share Transfer Agent (RTA) | MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited) |
🏢 The Corporate Identity: Aarey Drugs Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Aarey Drugs & Pharmaceuticals Limited operates as an integrated chemical manufacturer and bulk drug trading entity within India’s pharmaceutical ecosystem. The company operates across two complementary business channels: custom synthesis and manufacturing of active pharmaceutical ingredients (APIs) and advanced chemical intermediates, combined with large-scale industrial trading of industrial solvents, chemicals, and pharmaceutical raw materials.
The company maintains dedicated processing facilities in Tarapur, Maharashtra, producing synthetic intermediates essential for anti-diabetic, analgesic, respiratory, and anti-infective formulations. By leveraging trading volumes and in-house synthesis capabilities, Aarey Drugs optimizes operational cash flows and mitigates plant-level volume cyclicality.
- Dual Business Architecture: Merges high-margin API intermediate synthesis with high-volume industrial solvent and chemical trading.
- Strategic Manufacturing Base: Manufacturing plant situated in the Tarapur MIDC chemical belt provides direct proximity to Maharashtra’s port infrastructure and bulk chemical storage terminals.
- Essential API Portfolio: Synthesizes core bulk drugs including Metformin HCL, Mefenamic Acid, and Doxofylline.
The Founders, Promoters & Their Legacy
The company is promoted and managed by the Ghatalia family, led by Chairman and Managing Director Mihir Rajesh Ghatalia alongside Executive Director Nimit Rajesh Ghatalia. The promoter group collectively held a 37.71% equity stake in the enterprise as of March 31, 2026. Non-Executive Director Bina Rajesh Ghatalia serves on the Board, while Chief Financial Officer Mira Mihir Ghatalia oversees capital management and financial control.
The Journey: Corporate History & Key Milestones
Incorporated in 1990 in Maharashtra, Aarey Drugs & Pharmaceuticals Limited evolved from a regional chemical trading enterprise into a public limited pharmaceutical entity listed on both the BSE and NSE. Over three decades, the business scaled its production plant at MIDC Tarapur to manufacture core intermediate molecules such as Mono Methyl Urea, Dimethyl Urea, and 2-Bromomethyl 1,3-Dioxolane.
In recent fiscal years, the company expanded its financial base through preferential allotments and warrant issues, allocating capital toward plant expansion, internal efficiency upgrades, and working capital backstopping.
The Corporate Umbrella & Group Structure
Aarey Drugs & Pharmaceuticals Limited operates as a standalone operating entity. As disclosed in the statutory filings, the company has no subsidiaries, holding companies, joint ventures, or associate companies under Form AOC-1.
⚙️ The Business Engine: Aarey Drugs Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
The company operates under a single reportable primary business segment: Manufacturing and Trading of Bulk Drugs, Intermediates, and Chemicals. Total sales generated from trading activities stood at ₹472.27 Crores during FY 2025-26, compared to ₹473.94 Crores in FY 2024-25.
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
Aarey Drugs maintains a specialized catalog of chemical intermediates and active ingredients across core therapeutic categories. The production facility processes synthetic chemistries requiring controlled reaction parameters and hazardous solvent handling.
- Active Pharmaceutical Ingredients (APIs): Commercial manufacturing of Metformin HCL (anti-diabetic), Mefenamic Acid (non-steroidal anti-inflammatory), and Doxofylline (bronchodilator/respiratory).
- Advanced Chemical Intermediates: Synthesis of Mono Methyl Urea (MMU), Dimethyl Urea (DMU), Ortho Para Nitro Anisole (OPNA), Uracil, and 2-Bromomethyl 1,3-Dioxolane.
- Backward & Forward Integration Pipeline: Active development of domestic manufacturing capacities for Dimethylamine Hydrochloride (DMA-HCL), Ortho-Chlorobenzoic Acid, and Theophylline.
- Industrial Solvent Trading: Wholesale distribution of bulk chemical solvents, pharmaceutical raw materials, and organic reagents to domestic formulators.
The Names You Know: Key Brands & Flagship Portfolio
Aarey Drugs operates primarily as a business-to-business (B2B) bulk drug manufacturer and chemical distributor, supplying active ingredients and raw materials directly to institutional pharmaceutical formulators and industrial consumers.
Mapping the Domestic & Global Reach (India vs. Exports)
The majority of the company’s revenue is derived from domestic pharmaceutical clusters in Maharashtra, Gujarat, Telangana, and Andhra Pradesh. Export operations represent a secondary growth vector, supported by direct overseas deliveries.
| Geographic Market | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Domestic Sales & Distribution | 469.29 | 471.55 | -0.48% |
| Direct Export Earnings (FOB Value) | 2.98 | 2.39 | +24.69% |
| Total Foreign Exchange Consumed (Imports/Expenses) | 11.08 | 22.56 | -50.89% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The company’s industrial infrastructure comprises processing, storage, and administrative assets located across Maharashtra’s key industrial nodes:
- Tarapur Manufacturing Facility: Located at Plot E-34, MIDC Industrial Area, Tarapur, Boisar, Palghar District (Pincode 401506). Houses multi-purpose reaction vessels, fluid bed dryers, distillation columns, and dual-fuel boilers. Total finished production reached 574.76 MT in FY 2025-26.
- Head Office: Operating from 107, Sahakar Bhavan, Narshi Natha Street, Masjid Bunder, Mumbai (Pincode 400009) to handle procurement, trading desks, and commercial logistics.
- Quality Control & Analytical Lab: In-house analytical laboratory at the Tarapur plant dedicated to batch testing, assay verification, and raw material purity checks.
📊 The Financial Health: Aarey Drugs Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
The financial progression of Aarey Drugs over recent fiscal cycles demonstrates consistent revenue generation, backed by strong trading volumes and stable operational profits.
| Financial Metric | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 472.27 | 473.94 | -0.35% |
| Other Income | 6.10 | 9.81 | -37.82% |
| Total Income | 478.37 | 483.76 | -1.11% |
| EBITDA | 13.27 | 12.71 | +4.41% |
| Finance Costs | 5.00 | 4.66 | +7.30% |
| Depreciation & Amortisation | 2.85 | 1.94 | +46.91% |
| Profit Before Tax (PBT) | 5.41 | 6.10 | -11.31% |
| Profit After Tax (PAT) | 3.97 | 4.02 | -1.24% |
| Total Equity / Net Worth | 150.42 | 138.48 | +8.62% |
| Total Assets | 297.25 | 290.59 | +2.29% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
During FY 2025-26, Aarey Drugs recorded standalone Revenue from Operations of ₹472.27 Crores, representing a minor contraction of 0.35% from ₹473.94 Crores in FY 2024-25. Profit After Tax stood at ₹3.97 Crores compared to ₹4.02 Crores in the preceding period.
| Statement of Profit & Loss Line Item | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 472.27 | 473.94 | -0.35% |
| Other Income | 6.10 | 9.81 | -37.82% |
| TOTAL INCOME | 478.37 | 483.76 | -1.11% |
| Purchases of Stock-in-Trade & Raw Materials | 450.56 | 472.87 | -4.72% |
| Changes in Inventories of Finished Goods, WIP & Stock-in-Trade | 3.94 | -₹10.80 Crores | – |
| Employee Benefits Expense | 0.76 | 0.81 | -6.17% |
| Finance Costs | 5.00 | 4.66 | +7.30% |
| Depreciation and Amortisation Expenses | 2.85 | 1.94 | +46.91% |
| Other Expenses | 9.83 | 8.18 | +20.17% |
| TOTAL EXPENSES | 472.95 | 477.65 | -0.98% |
| Profit Before Tax (PBT) | 5.41 | 6.10 | -11.31% |
| Current Tax Expense | 1.59 | 1.40 | +13.57% |
| Deferred Tax (Credit / Charge) | -₹0.15 Crores | 0.17 | – |
| Short / (Excess) Provision for Earlier Years | 0.00 | 0.51 | -100.00% |
| PROFIT AFTER TAX (PAT) | 3.97 | 4.02 | -1.24% |
| Basic Earnings Per Share (₹) | 1.39 | 1.41 | -1.42% |
| Diluted Earnings Per Share (₹) | 1.39 | 1.41 | -1.42% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
The company’s total asset base expanded to ₹297.25 Crores as of March 31, 2026, supported by additions to fixed property assets, ongoing capital work-in-progress, and working capital receivables.
| Balance Sheet Line Item | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Property, Plant and Equipment | 17.66 | 16.22 | +8.88% |
| Capital Work-in-Progress (CWIP) | 8.12 | 0.00 | N/M |
| Non-Current Investments | 2.12 | 2.12 | 0.00% |
| Non-Current Loans and Advances | 0.00 | 0.98 | -100.00% |
| Other Non-Current Financial Assets | 6.41 | 5.67 | +13.05% |
| Total Non-Current Assets | 34.31 | 24.99 | +37.29% |
| Inventories | 41.54 | 45.48 | -8.66% |
| Trade Receivables | 129.65 | 133.46 | -2.85% |
| Cash and Cash Equivalents | 1.40 | 1.47 | -4.76% |
| Current Loans and Advances | 20.60 | 29.56 | -30.31% |
| Other Current Financial Assets | 2.00 | 1.76 | +13.64% |
| Other Current Assets | 67.75 | 53.88 | +25.74% |
| Total Current Assets | 262.94 | 265.60 | -1.00% |
| TOTAL ASSETS | 297.25 | 290.59 | +2.29% |
| EQUITY AND LIABILITIES | |||
| Equity Share Capital | 28.45 | 28.45 | 0.00% |
| Other Equity (Reserves & Surplus) | 118.20 | 107.51 | +9.94% |
| Share Application Money Pending Allotment | 3.77 | 2.52 | +49.60% |
| Total Equity (Net Worth) | 150.42 | 138.48 | +8.62% |
| Non-Current Borrowings | 0.97 | 1.99 | -51.26% |
| Deferred Tax Liabilities (Net) | 0.77 | 0.92 | -16.30% |
| Total Non-Current Liabilities | 1.75 | 2.91 | -39.86% |
| Current Borrowings | 48.99 | 32.87 | +49.04% |
| Trade Payables | 81.59 | 102.54 | -20.43% |
| Other Current Financial Liabilities | 0.00 | 0.00 | N/M |
| Other Current Liabilities | 10.79 | 9.66 | +11.70% |
| Short-Term Provisions | 2.12 | 2.73 | -22.34% |
| Current Tax Liabilities (Net) | 1.59 | 1.40 | +13.57% |
| Total Current Liabilities | 145.08 | 149.20 | -2.76% |
| Total Liabilities | 146.83 | 152.11 | -3.47% |
| TOTAL EQUITY AND LIABILITIES | 297.25 | 290.59 | +2.29% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
Management actively monitors key balance sheet ratios to evaluate liquidity and financial efficiency. Ratio movements exceeding 25% YoY trigger mandatory reporting explanations under Schedule III of the Companies Act, 2013.
| Financial Ratio | FY 2025-26 | FY 2024-25 | Management Explanation / Primary Driver | Latest YoY (%) |
|---|---|---|---|---|
| Current Ratio | 1.81x | 1.78x | Stable working capital ratio supported by current asset liquidations. | +1.69% |
| Debt-Equity Ratio | 0.33x | 0.25x | Exceeds 25% variance: Increased due to higher short-term borrowings drawn during the financial year. | +32.00% |
| Debt Service Coverage Ratio (DSCR) | 2.08x | 2.31x | Reflects higher interest obligations on working capital loans. | -9.96% |
| Inventory Turnover Ratio | 10.85x | 11.83x | Controlled inventory rotation across trading chemical stocks. | -8.28% |
| Trade Receivables Turnover Ratio | 3.59x | 2.98x | Faster collections and cash realisations from pharmaceutical buyers. | +20.47% |
| Trade Payables Turnover Ratio | 5.13x | 4.09x | Exceeds 25% variance: Increased due to quicker settlement of trade payables to vendor partners. | +25.43% |
| Net Capital Turnover Ratio | 4.01x | 4.07x | Consistent revenue conversion per unit of net working capital. | -1.47% |
| Net Profit Margin (%) | 3.97 | 0.85% | Stable net margins given high trading asset proportion. | – |
| Return on Capital Employed (ROCE %) | 6.85% | 7.62% | Marginal contraction due to asset additions and capital work-in-progress. | – |
| Return on Equity (ROE %) | 2.64% | 2.90% | Net earnings spread over expanded total equity base. | – |
Cash Flow: Tracking the Money Movement
The company generated operating cash flows of ₹10.14 Crores in FY 2025-26, which were allocated toward capital expenditure for plant expansion and working capital management.
| Cash Flow Statement Activity | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities (A) | 10.14 | 10.30 | -1.55% |
| Purchase of Property, Plant & Equipment / CWIP (CapEx) | 12.41 | 5.20 | +138.65% |
| Investments in Shares / Statutory Deposits | 0.00 | -₹0.74 Crores | – |
| Net Cash Used in Investing Activities (B) | -₹12.41 Crores | -₹5.94 Crores | – |
| Repayment / (Advance) of Long-Term Loans & Advances | -₹0.04 Crores | -₹1.52 Crores | – |
| Finance Costs Paid | -₹5.00 Crores | -₹4.66 Crores | – |
| Proceeds from Issue of Shares & Share Warrants / Premium | 8.00 | 1.70 | +370.59% |
| Net Cash Generated from / (Used in) Financing Activities (C) | 2.20 | -₹4.48 Crores | – |
| Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) | -₹0.07 Crores | -₹0.12 Crores | – |
| Cash and Cash Equivalents at Beginning of Year | 1.47 | 1.59 | -7.55% |
| Cash and Cash Equivalents at End of Year | 1.40 | 1.47 | -4.76% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Aarey Drugs expanded its capital investments during FY 2025-26, allocating ₹12.41 Crores toward property, plant, and equipment additions alongside ongoing capital work-in-progress of ₹8.12 Crores at Tarapur.
- Capital Work-in-Progress (CWIP): ₹8.12 Crores recorded as of March 31, 2026, designated for reaction vessel capacity expansion and utility efficiency upgrades.
- R&D Capital Expenditure: Direct capital addition of ₹0.41 Crores incurred during FY 2025-26 for laboratory equipment and testing infrastructure.
- Net Foreign Exchange Balance: Total foreign exchange outflow of ₹11.08 Crores exceeded direct export realisations of ₹2.98 Crores, resulting in net foreign exchange utilization of ₹8.10 Crores.
👥 Power & Control: Aarey Drugs Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The Board of Directors comprises six members, including two Executive Directors, three Non-Executive Independent Directors, and one Non-Executive Non-Independent Woman Director.
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mihir Rajesh Ghatalia | Chairman & Managing Director | 00581005 | Executive / Promoter |
| Nimit Rajesh Ghatalia | Executive Director | 07069841 | Executive / Promoter |
| Bina Rajesh Ghatalia | Non-Executive Director | 01471745 | Non-Executive Non-Independent Woman Director |
| Chetan Kiritbhai Mehta | Independent Director | 01639366 | Non-Executive Independent Director |
| Lalit Radhakrishna Tulsiani | Independent Director | 01538356 | Non-Executive Independent Director |
| Anil Mandal | Independent Director | 07328001 | Non-Executive Independent Director |
| Mira Mihir Ghatalia | Chief Financial Officer (CFO) | KMP | Key Managerial Personnel |
| Kailash Chand Jethlia | Company Secretary & Compliance Officer | KMP | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
As of March 31, 2026, the company’s total issued, subscribed, and paid-up equity share capital stood at 2,84,54,303 equity shares of face value ₹10 each. Promoters hold 37.71% of the equity capital, with the remaining balance held by public shareholders.
| Shareholder Category | Number of Shares Held | % of Total Issued Equity Shares |
|---|---|---|
| Promoter & Promoter Group | 1,07,02,443 | 37.61% |
| Public & Non-Institutional Shareholders | 1,77,51,860 | 62.39% |
| Total Issued Equity Shares | 2,84,54,303 | 100.00% |
- Bina Rajesh Ghatalia: 40,03,584 equity shares (14.12%).
- Mihir Rajesh Ghatalia: 28,35,888 equity shares (10.00%).
- Nimit Impex Private Limited: 20,10,000 equity shares (7.09%).
- Nimit Rajesh Ghatalia: 11,50,000 equity shares (4.06%).
- Mira Mihir Ghatalia: 6,50,000 equity shares (2.43%).
- Rajesh Pranlal Ghatalia: 2,971 equity shares (0.01%).
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
As confirmed in the statutory disclosures, Aarey Drugs & Pharmaceuticals Limited has no subsidiary, joint venture, or associate companies. Consequently, reporting under Form AOC-1 is not applicable.
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
The company maintains non-current strategic equity holdings alongside working capital credit facilities secured through primary banking partners.
- Strategic Equity Holdings: Non-current investments total ₹2.12 Crores, comprising quoted equity investments in Worth Investment & Trading Co. Ltd (₹1.72 Crores) and unquoted equity in Transmedia Software Ltd (₹0.40 Crores).
- Credit Rating: Acuité Ratings & Research maintained the company’s long-term credit rating at ACUITE BBB / Outlook: Stable for FY 2025-26.
- Working Capital Consortium: Credit limits secured from State Bank of India (Sakinaka Branch, Andheri East, Mumbai) backed by hypothecated inventory, plant equipment, and collateral properties.
- Contingent Tax Demands: Outstanding tax matters under appeal include disputed Income Tax demands u/s 143(1)(a)/147 totaling ₹2.16 Crores, GST Demand Orders u/s 73 under appeal before Appellate Tribunals totaling ₹9.04 Crores, and Maharashtra Value Added Tax (MVAT) disputes of ₹0.77 Crores.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Aarey Drugs operates within a specialized market niche by combining chemical synthesis with wholesale distribution.
- Integrated Supply Sourcing: Solvents and raw materials imported or traded in bulk feed directly into internal API intermediate manufacturing lines, lowering input costs.
- Established Synthesis Processes: Multi-decade manufacturing experience in hazardous reaction chemistries for urea derivatives (MMU/DMU) and dioxolane intermediates creates customer stickiness.
- Proximity to Chemical Hubs: Location within the Tarapur MIDC chemical zone offers direct connectivity to JNPT port facilities and regional pharmaceutical clusters.
What Could Go Wrong? Key Challenges & Business Risks
Management highlights key operational and regulatory risk factors affecting business continuity:
- Raw Material Price Volatility: Solvents and organic raw material prices fluctuate with global crude oil benchmarks, directly impacting trading margins.
- Regulatory & Environmental Compliance: Manufacturing plants face strict safety standards administered by the Maharashtra Pollution Control Board (MPCB).
- Litigation & Secretarial Non-Compliances: Secretarial audit disclosures note delayed filings and unresolved listing approvals for 1,00,000 equity shares withheld by stock exchanges.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
The company’s operational growth strategy focuses on expanding internal reaction capacities at the Tarapur plant while deepening backward integration capabilities.
- Capacity Expansion: Expanding production lines for high-demand intermediates to support volume growth in key market segments.
- Backward Integration Projects: Developing domestic synthesis lines for Dimethylamine Hydrochloride (DMA-HCL) and Ortho-Chlorobenzoic Acid to reduce reliance on imported raw materials.
- API Line Additions: Expanding manufacturing capabilities for respiratory active ingredients like Theophylline alongside core Metformin HCL production lines.
The Verdict: Strategic Outlook & Conclusion
Aarey Drugs & Pharmaceuticals Limited maintains a stable market position supported by its dual revenue model of API intermediate production and chemical trading. As the company advances its ongoing capital expenditure initiatives and backward integration projects at Tarapur, its operational foundation remains aligned with growth trends across India’s active pharmaceutical ingredient industry.
Frequently Asked Questions (FAQs) About Aarey Drugs
Q1: What does Aarey Drugs & Pharmaceuticals Limited manufacture?
Aarey Drugs manufactures chemical intermediates (Mono Methyl Urea, Dimethyl Urea, 2-Bromomethyl 1,3-Dioxolane) and Active Pharmaceutical Ingredients (Metformin HCL, Mefenamic Acid, Doxofylline), while also trading industrial solvents and bulk chemicals.
Q2: What were the revenue and net profit of Aarey Drugs in FY 2025-26?
In FY 2025-26, Aarey Drugs reported standalone Revenue from Operations of ₹472.27 Crores and a Net Profit After Tax (PAT) of ₹3.97 Crores.
Q3: Who are the promoters and Managing Director of the company?
The company is promoted by the Ghatalia family. Mihir Rajesh Ghatalia serves as Chairman & Managing Director, Nimit Rajesh Ghatalia serves as Executive Director, and Bina Rajesh Ghatalia serves as Non-Executive Director.
Q4: Where are the manufacturing facilities of Aarey Drugs located?
The primary manufacturing plant is located at Plot E-34, MIDC Industrial Area, Tarapur, Boisar, Palghar District, Maharashtra (Pincode 401506).
Q5: What is the debt profile and credit rating of Aarey Drugs?
As of March 31, 2026, total borrowings stood at ₹49.96 Crores (comprising ₹0.97 Crores of long-term debt and ₹48.99 Crores of short-term working capital debt). The company holds an active credit rating of ACUITE BBB / Stable from Acuité Ratings & Research.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.aareydrugs.com